Everest Medicines Announces Transformational Global Licensing Deal for Civorebrutinib with Travere Therapeutics
Key Highlights for Investors
- Exclusive License Agreement: On June 2, 2026, Everest Medicines (Singapore) Pte. Ltd., a wholly-owned subsidiary of Everest Medicines Limited, signed an exclusive license and collaboration agreement with Travere Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company (TVTX).
- Upfront and Milestone Payments: Everest will receive an upfront payment of US\$112.5 million from Travere. The agreement also includes potential milestone payments of up to US\$1.03 billion across development, regulatory, and commercial achievements for up to five different indications.
- Royalties: Everest is eligible for tiered royalties ranging from high single-digit to double-digit percentages based on future annual net sales thresholds of civorebrutinib.
- Territorial Scope: Travere receives exclusive, worldwide commercialization rights for civorebrutinib, excluding Greater China and certain countries in East and Southeast Asia, which remain with Everest.
- Product Pipeline: Civorebrutinib (EVER001) is being positioned as a “pipeline-in-a-product” with planned clinical development in multiple rare immune-mediated kidney diseases, including primary membranous nephropathy (PMN), immune-mediated focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD), with possible further indications.
Strategic and Financial Impact
- This transaction is a significant non-dilutive financing event for Everest, potentially strengthening its balance sheet and supporting further research and development.
- The agreement accelerates the global development and commercialization of civorebrutinib, increasing the likelihood of reaching patients worldwide and unlocking substantial value for shareholders should key milestones be achieved.
- The total potential value of US\$1.1425 billion (including upfront and milestones) is highly significant relative to Everest’s market capitalization and could be materially price sensitive.
- The deal does not constitute a notifiable transaction under Chapter 14 of the Hong Kong Listing Rules, as it is of a revenue nature in the ordinary and usual course of business.
Background on Travere Therapeutics and Civorebrutinib
- Travere Therapeutics is a global rare disease-focused biopharma with a strong track record in developing and delivering therapies for underserved patient populations.
- Civorebrutinib (EVER001) is a next-generation, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in global development for renal diseases. BTK is critical in B-cell receptor signaling, and BTK inhibitors have shown promise in B-cell autoimmune diseases.
- The successful development and commercialization of civorebrutinib are not guaranteed; investors should be aware of clinical and regulatory risks.
Board Statement and Shareholder Considerations
- The Everest board believes the agreement is in the best interests of the company and shareholders as a whole, given the potential to bring innovative therapies to market and create substantial new revenue streams.
- Travere and its beneficial owners are independent third parties; there are no connected party issues.
- Shareholders and potential investors are advised to exercise due care, as the final milestone payments and commercial success of civorebrutinib remain uncertain.
Potential Share Price Impact
- This is a major licensing transaction with significant upfront and milestone payments and global commercialization potential for a key pipeline asset. It is likely to be price sensitive and could positively affect Everest Medicines’ share price if the market values the deal and the de-risking of the asset highly.
- However, risks remain over clinical development, regulatory approval, and commercialization success.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The successful development and commercialization of civorebrutinib are subject to significant clinical and regulatory risks. Investors should exercise caution and consult their own advisors before making investment decisions.
珠峰醫藥與Travere Therapeutics簽署重磅全球授權協議，推動Civorebrutinib全球開發
投資者重點
- 獨家授權協議：2026年6月2日，珠峰醫藥全資子公司Everest Medicines（Singapore）Pte. Ltd.與納斯達克上市生物製藥公司Travere Therapeutics, Inc.（TVTX）簽署獨家授權及合作協議。
- 預付款及里程碑：珠峰醫藥將獲得1.125億美元預付款，並有機會根據多達五個適應症達成開發、監管及商業化相關里程碑獲取高達10.3億美元的額外付款。
- 版稅收入：未來根據年度淨銷售額門檻，有資格獲得高單位數到雙位數百分比的分級版稅收入。
- 區域範圍：Travere獲得除大中華區及東南亞部分國家以外的全球獨家開發及商業化權利，相關地區權益仍由珠峰醫藥保留。
- 產品管線：Civorebrutinib（EVER001）計劃在多種罕見免疫性腎病如PMN、FSGS及MCD開展臨床研究，並有進一步擴展適應症的潛力。
戰略及財務影響
- 本交易為公司帶來重大無稀釋性資金，有助於加強資產負債表並支持研發活動。
- 協議加速civorebrutinib的全球開發及商業化，有望為公司及股東釋放潛在巨大價值（若關鍵里程碑達成）。
- 總潛在交易價值達11.425億美元，對公司市值有重大影響，或為極具價格敏感的消息。
- 根據香港上市規則第14章，該交易屬於日常業務性質，無需作為須予披露交易。
Travere Therapeutics及Civorebrutinib簡介
- Travere Therapeutics專注於全球罕見病領域，擁有豐富的開發及推廣罕見病治療經驗。
- Civorebrutinib（EVER001）為新一代、可逆性共價Bruton酪氨酸激酶（BTK）抑制劑，全球開發用於腎臟疾病。BTK為B細胞信號通路關鍵蛋白，已被證實在B細胞自體免疫疾病中具治療潛力。
- 產品最終能否成功開發及商業化尚存不確定性，投資者需留意相關風險。
董事會聲明及股東須知
- 董事會認為協議符合公司及全體股東最佳利益，有助於加快創新療法上市及開拓全新收入來源。
- Travere及其最終權益擁有人與本公司無關連關係。
- 股東及潛在投資者應審慎行事，因最終里程碑支付及產品商業化存在不確定性。
潛在股價影響
- 此為公司關鍵管線資產的大型全球授權交易，包含可觀的預付款及里程碑，具高度價格敏感性，若獲市場認同有望推動股價上升。
- 惟產品臨床、監管及商業化風險仍需關注。
聲明：本文僅供資訊參考，並不構成投資建議。Civorebrutinib最終能否成功開發及上市存在重大臨床及監管風險。投資者應審慎決策並諮詢專業顧問。
